INDOCO

** Indoco Remedies INRM.NS slips as much as 6.4% to 216.07 rupees

** Pharma co's clinical research organisation AnaCipher completes 5-day comprehensive U.S. Food and Drug Administration (FDA) inspection

** Facility gets Form 483 - a notice of violations or issues found in co's practices or products, indicating non-compliance with regulations

** Co did not specify the issues found

** INRM last down 3.5%, extending YTD losses to 30.5%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

March 10 (Reuters) - Indoco Remedies Ltd INRM.NS:

• ANACIPHER COMPLETES US FDA INSPECTION

• FACILITY RECEIVED ONE FORM 483 AT END OF INSPECTION

Source text: ID:nBSE5XTyjs

Further company coverage: INRM.NS

(([email protected];;))

Feb 12 (Reuters) - Indoco Remedies Ltd INRM.NS:

• GETS NOTICE FOR POTENTIAL TAX DEMAND OF 85 MILLION RUPEES

Source text: ID:nBSE34Vz9y

Further company coverage: INRM.NS

(([email protected];;))

** Shares of pharmaceutical co Indoco Remedies Ltd INRM.NS fall ~11% to 304 rupees, set for biggest one-day pct decline since January 2023

** Prabhudas Lilladher downgrades stock to 'hold' from 'accumulate', raises PT slightly to 325 rupees from 320 rupees

** Brokerage says Q3 U.S. sales were impacted by warning letter from FDA for a manufacturing plant in Goa

** Says, FY26 and FY27 margins to be hit by lower sales across regulated markets and ongoing remediation costs in relation to the letter

** INRM's headcount and repair & maintenance expenses will remain elevated - brokerage

** Cuts FY26 EPS estimate by 74.3% to 3.2 rupees and FY27 EPS estimate by 23.5% to 12.5 rupees

** Stock rated 'hold' on avg by 3 analysts, with median PT at 325 rupees- LSEG data

** Stock down 17.5% in last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Jan 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• DEC-QUARTER CONSOL NET LOSS 263.9 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.02 BILLION RUPEES

Source text: ID:nBSEv9z6N

Further company coverage: INRM.NS

(([email protected];;))

Dec 17 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - WARNING LETTER FROM USFDA FOR GOA FACILITY

• INDOCO REMEDIES - CONTINUE TO SUPPLY PRODUCTS FROM GOA FACILITY

Source text: ID:nBSE4zQYKc

Further company coverage: INRM.NS

(([email protected];))

** Shares of Indoco Remedies INRM.NS rise 6.2% to 342 rupees

** Pharmaceuticals co enters into distribution partnership with UK-based Clarity Pharma

** Co will launch around 20 products over next 18 months through Clarity Pharma as its distributor in UK

** Trading vols at 287,516, 2.1x 30-day average

** INRM down ~12% YTD

(Reporting by Vijay Malkar)

(([email protected];))

Dec 2 (Reuters) - Indoco Remedies Ltd INRM.NS:

• ANNOUNCES STRATEGIC DISTRIBUTION PARTNERSHIP WITH CLARITY PHARMA, UK

• WILL LAUNCH AROUND 20 PRODUCTS OVER NEXT 18 MONTHS THROUGH CLARITY PHARMA

• WILL LAUNCH AROUND 20 PRODUCTS OVER 18 MONTHS THROUGH CLARITY PHARMA IN UK

• WILL CONTINUE TO SUPPLY ALL PRODUCTS UNDER EXISTING B2B PARTNERSHIP TO CLIENTS

Source text: ID:nBSE6S0M60

Further company coverage: INRM.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS rise as much as 5% to 317.50 rupees

** Co gets U.S. FDA approval for varenicline tablets, which are used to help quit smoking

** INRM last up about 2%, set to snap nine-session losing streak

** Stock still down ~22% so far this year, on track for third straight year of losses

** YTD, peers Pfizer Ltd PFIZ.NS and Ajanta Pharma AJPH.NS up ~20% and ~43%, respectively

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Oct 24 (Reuters) - Indoco Remedies Ltd INRM.NS:

• SEPT-QUARTER CONSOL NET LOSS 95.7 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.31 BILLION RUPEES

Source text for Eikon: ID:nnAPN2BSNML

Further company coverage: INRM.NS

(([email protected];;))

Oct 11 (Reuters) - Indoco Remedies Ltd INRM.NS:

• USFDA DETERMINS INSPECTION CLASSIFICATION OF GOA FACILITY OFFICIAL ACTION INDICATED

Source text for Eikon: ID:nBSE5wncb0

Further company coverage: INRM.NS

(([email protected];;))

Oct 4 (Reuters) - Indoco Remedies Ltd INRM.NS:

• FINAL ANDA APPROVAL FROM THE USFDA FOR CETIRIZINE HYDROCHLORIDE TABLETS USP, 10 MG (OTC)

Source text for Eikon: ID:nBSE4Rg7Jk

Further company coverage: INRM.NS

(([email protected];;))

Aug 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - RECEIVES FINAL ANDA APPROVAL FROM USFDA FOR LOFEXIDINE TABLETS

• INDOCO REMEDIES - ANDA APPROVAL FOR LOFEXIDINE TABLETS WITH COMPETITIVE GENERIC THERAPY DESIGNATION

Source text for Eikon: ID:nBSE6S1J8Q

Further company coverage: INRM.NS

(([email protected];))

July 23 (Reuters) - Indoco Remedies Ltd INRM.NS:

• JUNE-QUARTER CONSOL NET PROFIT 26.2 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.24 BILLION RUPEES

Source text for Eikon: ID:nBSE92PYtL

Further company coverage: INRM.NS

(([email protected];))

June 6 (Reuters) - Indoco Remedies Ltd INRM.NS:

• RECEIVES TENTATIVE ANDA APPROVAL FROM USFDA FORCANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS

Further company coverage: INRM.NS

(([email protected];))

May 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - RECEIVES FINAL ANDA APPROVAL FROM USFDA FOR PREGABALIN CAPSULES

• INDOCO REMEDIES LTD - PREGABALIN CAPSULES WILL BE MANUFACTURED BY CO AT GOA

Source text for Eikon: ID:nBSEbsFHD4

Further company coverage: INRM.NS

(([email protected];))

** Shares of pharmaceuticals company Indoco Remedies INRM.NS fall 2% to 321 rupees

** Co reports a 12% fall in Q4 net profit as costs surge

** Stock opened 1.2% higher ahead of the results, and rose as much as 2.24%

** INRM trading below its 100-day and 200-day simple moving averages since mid-April

** Stock down 2.7% so far in May, eyes fifth consecutive session of falls

($1 = 83.4975 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

March 25 (Reuters) - Indoco Remedies Ltd INRM.NS:

• UNIT WARREN REMEDIES COMMENCED COMMERCIAL PRODUCTION FROM AURANGABAD MANUFACTURING FACILITY

• UNIT COMMENCES COMMERCIAL PRODUCTION OF PHARMACEUTICAL INTERMEDIATES

Source text for Eikon: ID:nBSE553kkm

Further company coverage: INRM.NS

(([email protected];))

Jan 23 (Reuters) - Indoco Remedies Ltd INRM.NS:

• DEC-QUARTER CONSOL NET PROFIT 163 MILLION RUPEES VERSUS PROFIT 281.5 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.59 BILLION RUPEES VERSUS 4.11 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: INRM.NS

(([email protected];))

** Shares of Indoco Remedies INRM.NS climb as much as 4.97% to 404.70 rupees, highest since Jan. 24, 2023

** Pharmaceutical products maker gets tentative approval from U.S. FDA for Canagliflozin tablets, 100 mg and 300 mg

** Drug used to treat adults with type 2 diabetes mellitus; to be manufactured at INRM's facility in Goa

** Trading volume is ~464,500 shares as of 3:10 p.m. IST, 3.2 times the 30-day avg - LSEG data

** INRM down 2.34% in 2023 so far, including session's gains

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Oct 19 (Reuters) - Indoco Remedies Ltd INRM.NS:

• A PRE-APPROVAL INSPECTION WAS CONDUCTED BY USFDA AT CO’S SOLID ORAL FORMULATION FACILITY (PLANT I) LOCATED AT GOA

• PRE-APPROVAL INSPECTION WAS CONDUCTED FOR TWO DRUG PRODUCT APPLICATIONS (ANDAS) FILED FROM FACILITY

• INDOCO REMEDIES LTD - USFDA HAS ISSUED ‘FOUR OBSERVATIONS’ IN FORM 483 AT END OF PRE-APPROVAL INSPECTION

Further company coverage: INRM.NS

(([email protected];))

Sept 7 (Reuters) - Indoco Remedies Ltd INRM.NS:

• AMOUNT OF LOSS DUE TO FIRE AT AURANGABAD PLANT IS ABOUT 78.6 MILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: INRM.NS

(([email protected];))

Aug 28 (Reuters) - Indoco Remedies Ltd INRM.NS:

• AMOUNT OF LOSS DUE TO JULY 29 FIRE IS APPROXIMATELY 78.6 MILLION RUPEES

Source text for Eikon: ID:nBSE7NdcXx

Further company coverage: INRM.NS

(([email protected];))

Aug 4 (Reuters) - Indoco Remedies Ltd INRM.NS:

• PRODUCTION OPERATIONS AT AURANGABAD PLANT WAS TEMPORARILY DISRUPTED DUE TO FIRE ACCIDENT ON JULY 29

• PRODUCTION OPERATIONS AT PLANT HAS BEEN RESUMED FROM AUGUST 3, 2023

Source text for Eikon: ID:nBSE8zB6Nx

Further company coverage: INRM.NS

(([email protected];))

July 26 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO’S BADDI FACILITY (UNIT I) RECEIVES GMP CERTIFICATION FROM EU HEALTH AUTHORITY

Source text for Eikon: [ID:]

Further company coverage: INRM.NS

(([email protected];))

July 25 (Reuters) - Indoco Remedies Ltd INRM.NS:

• JUNE-QUARTER CONSOL NET PROFIT 243.9 MILLION RUPEES VERSUS PROFIT 385.7 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.17 BILLION RUPEES VERSUS 3.95 BILLION RUPEES

Source text for Eikon: ID:nBSE5yDm68

Further company coverage: INRM.NS

(([email protected];))

July 11 (Reuters) - Indoco Remedies Ltd INRM.NS:

• COMPLETION OF INSPECTION AT INDOCO REMEDIES LIMITED GOA PLANT-III

• GERMAN HEALTH AUTHORITY INSPECTED CO'S MANUFACTURING FACILITY (PLANT III) LOCATED AT GOA FOR ORAL DOSAGE FORM

• FACILITY HAS RECEIVED EU GMP CERTIFICATION FROM COMPETENT HEALTH AUTHORITY OF GERMANY

• GMP CERTIFICATION CONFIRMS THAT FACILITY COMPLIES WITH GOOD MANUFACTURING PRACTICE REQUIREMENTS AS REFERRED IN EC DIRECTIVE

Source text for Eikon: ID:nBSEb3GzMs

Further company coverage: INRM.NS

(([email protected];))

June 9 (Reuters) - Indoco Remedies Ltd INRM.NS:

• COMPLETION OF INSPECTION AT INDOCO REMEDIES LIMITED BADDI PLANT-III

• FACILITY HAS RECEIVED EU GMP CERTIFICATION FROM GERMAN HEALTH AUTHORITY

• FACILITY COMPLIES WITH GOOD MANUFACTURING PRACTICE REQUIREMENTS AS REFERRED IN EC DIRECTIVE

Source text for Eikon: ID:nBSE2ByY9z

Further company coverage: INRM.NS

(([email protected];;))

June 6 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO ACQUIRES 85% STAKE IN US BASED FPP HOLDING COMPANY, LLC

• ACQUIRED 85% STAKE IN FPP FOR $4 MILLION FROM CONTRACT PHARMACAL CORP

Source text for Eikon: ID:nNSE8kw4R4

Further company coverage: INRM.NS

(([email protected];))

** Shares of pharmaceutical products manufacturer Indoco Remedies Ltd INRM.NS down as much as 4.6% to 331.8 rupees, their lowest since May 10

** Co hits sharpest intraday pct loss since March 16

** On track for third consecutive session of losses, if trends hold

** INRM reports 36.2% y/y fall in consolidated net profit for the quarter ended March 31 at 258.1 mln rupees ($3.16 mln)

** Brokerages bullish on co with all seven firms rating stock "buy" or above, median PT is 443 rupees

** About 273,422 shares change hands as of 2:03 p.m. IST, vs 2.6x the 30-day average

** Stock down 14.5% YTD as of last close

($1 = 81.7800 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected];))